Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Upcoming Educational Summit to Focus on Inhibitors
 

Patients, advocates and medical professionals will gather next month to discuss key topics associated with inhibitors in hemophilia. The Inhibitor Patient Education Summit will focus on joint health, treatment, pain management, reimbursement, psychosocial and other important issues. The event, sponsored by the pharmaceutical company Novo Nordisk, will be held at the Courtyard Marriott in Philadelphia, PA on November 5-6, 2005.

“The Inhibitor Patient Education Summit is a much-needed forum where individuals with hemophilia and inhibitors and care providers can interact. It is our desire to run this program on an annual basis,” said Mike Sumner, MD, senior director of clinical affairs
for Novo Nordisk.

An inhibitor can develop when individuals with hemophilia produce an antibody response to certain factor products, rendering treatment with these products ineffective. Approximately 15% to 30% of people with severe hemophilia A experience this complication. Inhibitor development in patients with severe hemophilia B is somewhat less common, occurring in about 1% to 4% of that population.

To register or to learn more about the meeting call 1-888-706-6867 or go to www.inhibitorsummits.com.

 

This section of our Web site is sponsored by: